ZSAN · Zosano Pharma Corp

-

Please sign in to comment on ZSAN

1 Comment

Admin

4 years, 1 month ago

Zosano Pharma Corporation is currently in a long term downtrend where the price is trading 6.4% below its 200 day moving average.

From a valuation standpoint, the stock is 71.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 375.9.

Zosano Pharma Corporation's total revenue rose by inf% to $224K since the same quarter in the previous year.

Its net income has increased by 100.0% to $0 since the same quarter in the previous year.

Finally, its free cash flow grew by 14.8% to $-7M since the same quarter in the previous year.

Based on the above factors, Zosano Pharma Corporation gets an overall score of 4/5.

CurrencyCode	USD
Sector	Healthcare
Industry	Biotechnology
Exchange	NASDAQ
ISIN	US98979H3012

Target Price	21
Dividend Yield	0.0%
PE Ratio	None
Beta	3.29
Market Cap	3M

ABOUT

Zosano Pharma Corp

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

ZSAN · Zosano Pharma Corp

-

Zosano Pharma Corp

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Zosano Pharma Corp using a moving average strategy